96.30
-0.83(-0.85%)
Currency In USD
| Previous Close | 97.13 |
| Open | 97.14 |
| Day High | 98.99 |
| Day Low | 96.08 |
| 52-Week High | 103.89 |
| 52-Week Low | 47.25 |
| Volume | 986,717 |
| Average Volume | 1M |
| Market Cap | 6.27B |
| PE | 22.98 |
| EPS | 4.19 |
| Moving Average 50 Days | 86.32 |
| Moving Average 200 Days | 68.08 |
| Change | -0.83 |
Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection
GlobeNewswire Inc.
Mar 06, 2026 9:01 PM GMT
PYLARIFY TruVu™ (piflufolastat F 18) Injection PYLARIFY TruVu™ (piflufolastat F 18) Injection, a new formulation of Lantheus' widely-used U.S. market-leading PSMA PET imaging agent that combines the diagnostic performance of PYLARIFY® (piflufolast
Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to LUTATHERA®
GlobeNewswire Inc.
Mar 02, 2026 1:30 PM GMT
BEDFORD, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver b
Lantheus to Present at March 2026 Investor Conferences
GlobeNewswire Inc.
Feb 24, 2026 1:30 PM GMT
BEDFORD, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver bette